Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
- Positive topline data from the Phase 1b MAD Clinical Trial of RGLS8429 for ADPKD
- Oversubscribed $100 million private placement to extend cash runway
- Completed enrollment of the third cohort in the MAD study with data expected in mid-2024
- Successful Type D Meeting with FDA for accelerated approval pathway for RGLS8429
- None.
Insights
The recent announcement by Regulus Therapeutics Inc. regarding the positive topline data from their Phase 1b MAD study of RGLS8429 presents a significant milestone for investors to consider. The biopharmaceutical sector is highly sensitive to clinical trial outcomes, as they are strong indicators of a drug's potential market success. The positive data suggest that RGLS8429 could be a viable treatment for ADPKD, a disease with limited therapeutic options. This could translate into a competitive advantage and a new revenue stream for Regulus if the drug reaches the market.
From a financial perspective, the oversubscribed private placement is a strong vote of confidence from institutional investors, signaling a robust interest in the company's growth prospects. The $100 million capital infusion extends the company's operational runway, which is important for sustaining long-term R&D efforts without the immediate need for further dilutive financing. This financial stability is likely to be viewed favorably by the market, as it reduces short-term financial risk and underlines the company's potential for growth.
However, it is important to note that the drug is still in early stages of development and there are several regulatory hurdles ahead. The FDA's willingness to consider an accelerated approval pathway is promising, yet investors should remain cautious until more substantial efficacy and safety data are available. Furthermore, the increase in R&D expenses year-over-year reflects the company's investment in advancing their pipeline, which could pressure short-term financials but is necessary for long-term value creation.
The clinical progress of RGLS8429, as reported by Regulus Therapeutics, is noteworthy for stakeholders within the medical research community. The observed dose response and the correlation with improvements in kidney volume and function are particularly significant, as they provide evidence of the drug's biological activity and potential therapeutic impact. The use of urinary polycystin levels as a biomarker is a strategic approach in demonstrating the drug's mechanism of action in ADPKD, a complex renal disorder characterized by cyst formation and progressive kidney enlargement.
Moreover, the exploratory results regarding reductions in height-adjusted total kidney volume (htTKV) and total kidney cyst volume (TKCV) in patients are encouraging. These parameters are critical in assessing the progression of ADPKD and could serve as surrogate endpoints in future clinical trials. The decision to increase the sample size in cohort 4 is a prudent step to enhance the robustness of the data. As the company progresses towards higher dosing in upcoming cohorts, the medical research community will be closely monitoring the safety profile of RGLS8429, as well as its efficacy in a larger patient population.
It is also essential to consider the implications of the Type D meeting with the FDA, which suggests a pathway for expedited approval based on TKV reduction. While this accelerates the drug's potential time to market, the requirement for a post-approval Phase 3 trial to demonstrate improvement in estimated glomerular filtration rate (eGFR) introduces an additional layer of complexity and risk. The outcome of these trials will be pivotal in determining the drug's long-term viability and its ability to meet the unmet needs of the ADPKD patient population.
Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Oversubscribed
Completed enrollment of the third cohort of patients in the MAD study; Data anticipated mid-2024
Completed Type D Meeting with FDA to Discuss Pathway for Accelerated Approval of RGLS8429
"2023 was a productive year for Regulus, and the growing momentum in our Phase 1b MAD study of RGLS8429 is further emphasized by our announcement of key milestones and data readouts, including the recent positive topline data from the second cohort of patients. In the topline data, we saw evidence of a mechanistic dose response at a 2 mg/kg dose level based on urinary polycystin levels and in particular their potential correlation with improvements in kidney volume and function" said Jay Hagan, CEO of Regulus. "Thanks to the strong data we've seen to date and the ongoing support of our shareholders, we completed an oversubscribed
Program Updates
RGLS8429 for ADPKD: In March 2024, the Company shared positive topline data from the second cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. In the second cohort, 14 patients were randomized 3:1 to receive either 2 mg/kg of RGLS8429 or placebo every other week for three months. RGLS8429 was well tolerated with no safety findings of concern. Greater biological activity of RGLS8429 was observed at 2 mg/kg based on urinary polycystin levels compared to 1mg/kg and placebo, which was most evident after 3 months of dosing. Exploratory results of imaging-based biomarkers were encouraging with 3 patients with the highest increases in PC1 and PC2 having reductions in height-adjusted total kidney volume (htTKV) >
The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. The study is evaluating RGLS8429 treatment across three different weight-based dose levels, including measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), htTKV, cyst architecture, and overall kidney function.
In November 2023, Regulus announced it had dosed the first patient in the third cohort of the Phase 1b MAD study. This cohort is receiving 3 mg/kg of RGLS8429 or placebo every other week for three months. In January, the Company announced that it had completed enrollment in cohort 3 with top-line data expected in mid-2024.
In late 2023, Regulus amended the protocol for the Phase 1b MAD study to include a fourth cohort that will receive an open label fixed dose of 300 mg of RGLS8429 that will provide higher exposure in a larger number of patients based on anticipated body weight in order to compare biomarker and safety data to the weight-based dosing, with initiation of screening planned for Q2 2024. Based on the results from the second cohort, the Company plans to amend the protocol to increase the sample size to up to 30 patients in cohort 4.
In December 2023, the Company held a successful Type D meeting with the
Corporate Highlights
Closed Oversubscribed
Financial Results
Cash and Cash Equivalents: As of December 31, 2023, Regulus had
Research and Development (R&D) Expenses: Research and development expenses were
General and Administrative (G&A) Expenses: General and administrative expenses were
Net Loss: Net loss was
About ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately
About RGLS8429
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound, RGLS4326. Regulus announced completion of the Phase 1 SAD study in September 2022. The Phase 1 SAD study demonstrated that RGLS8429 has a favorable safety and PK profile. RGLS8429 was well-tolerated with no serious adverse events reported and plasma exposure was approximately linear across the four doses tested and is similar to the PK data from the first-generation compound. In the Phase 1b MAD study Regulus announced both top line data from the first cohort of patients in September 2023 and from the second cohort of patients in March 2024. After review of all available safety data from the second cohort, Regulus has advanced to the third cohort where dosing has begun, and patients are receiving 3 mg/kg of RGLS8429 or placebo every other week for three months. Regulus announced completion of enrollment in the third cohort in January 2024 with top-line data anticipated in mid-2024.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
Forward-Looking Statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, the expected timing for initiating clinical studies, potentially achieving therapeutic efficacy and the potential to address the underlying genetic causes of ADPKD, the expected timing for reporting data, the timing and future occurrence of other preclinical and clinical activities the potential accelerated approval pathway, the expected length of our cash runway and other statements relating to future events or conditions. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, preliminary or initial results may not be indicative of future results, preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and our need for additional capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' most recently filed annual report on Form 10-K for the fourth quarter and year ending December 31, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Regulus Therapeutics Inc. Selected Financial Information Condensed Statement of Operations (In thousands, except share and per share data) | |||||||||||||||
Three months ended December 31, | Year ended December 31, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Operating expenses: | |||||||||||||||
Research and development | 5,762 | 4,713 | 21,152 | 18,410 | |||||||||||
General and administrative | 2,538 | 2,219 | 9,957 | 9,829 | |||||||||||
Total operating expenses | 8,300 | 6,932 | 31,109 | 28,239 | |||||||||||
Loss from operations | (8,300) | (6,932) | (31,109) | (28,239) | |||||||||||
Other income (expense), net | 239 | 137 | 1,073 | (83) | |||||||||||
Loss before income taxes | (8,061) | (6,795) | (30,036) | (28,322) | |||||||||||
Income tax expense | - | - | (1) | (1) | |||||||||||
Net loss | $ | (8,061) | $ | (6,795) | $ | (30,037) | $ | (28,323) | |||||||
Net loss per share, basic and diluted | $ | (0.40) | $ | (0.40) | $ | (1.58) | $ | (1.86) | |||||||
Weighted average shares used to compute basic and diluted
| 20,222,111 | 16,839,700 | 18,960,401 | 15,259,958 | |||||||||||
December 31, | December 31, | |||||
Cash, cash equivalents and short-term investments | $ | 23,767 | $ | 39,160 | ||
Total assets | 30,750 | 46,716 | ||||
Term loan, less debt issuance costs | 1,334 | 4,511 | ||||
Stockholders' equity | 21,187 | 33,291 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent-updates-302096347.html
SOURCE Regulus Therapeutics Inc.
FAQ
What is the Phase 1b MAD Clinical Trial of RGLS8429 for?
What was the amount of the oversubscribed private placement recently completed by Regulus?
When is the data from the third cohort of patients in the MAD study expected?
What was discussed in the Type D Meeting with the FDA?
What was the cash and cash equivalents balance of Regulus as of December 31, 2023?
